ALIVUS

Alivus Life Sciences Share Price

 

 

Alivus Life Sciences live price: ₹1046.25. It opened at ₹1,043 vs previous close ₹1,043; intraday high/low: ₹1,051/₹1,030. The 50 & 200 DMA stand at ₹951.57/₹947.32.

Alivus Life Sciences Performance

  • Today's Low
  • ₹1,030
  • Today's High
  • ₹1,051
  • 52 Week Low
  • ₹819
  • 52 Week High
  • ₹1,225
  • Open Price₹1,043
  • Previous Close₹1,043
  • Volume54,170
  • 50 DMA₹951.57
  • 100 DMA₹938.68
  • 200 DMA₹947.32

Investment Returns

  • Over 1 Month + 11.37%
  • Over 3 Month + 17.87%
  • Over 6 Month + 12.04%
  • Over 1 Year + 8.39%

Smart Investing Starts Here Start SIP with Alivus Life Sciences for Steady Growth!

Invest Now

Alivus Life Sciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 23.6
  • PEG Ratio
  • 1
  • Market Cap Cr
  • 12,841
  • P/B Ratio
  • 4.1
  • Average True Range
  • 35.58
  • EPS
  • 45.82
  • Dividend Yield
  • 0.5
  • MACD Signal
  • 22.46
  • RSI
  • 73.69
  • MFI
  • 76.36

Alivus Life Sciences Financials

Alivus Life Sciences Technicals

EMA & SMA

Current Price
₹1,046.25
+ 3.7 (0.35%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹985.82
  • 50 Day
  • ₹951.57
  • 100 Day
  • ₹938.68
  • 200 Day
  • ₹947.32

Resistance and Support

1042.42 Pivot Speed
  • R3 1,075.83
  • R2 1,063.42
  • R1 1,054.83
  • S1 1,033.83
  • S2 1,021.42
  • S3 1,012.83

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Glenmark Life Sciences develops and manufactures high-quality Active Pharmaceutical Ingredients (APIs), supplying over 130 molecules to more than 700 global pharmaceutical companies. With world-class manufacturing and research capabilities, GLS focuses on operational excellence, regulatory compliance, and innovation.

Alivus Life Sciences Limited has an operating revenue of Rs. 2,512.26 Cr. on a trailing 12-month basis. An annual revenue growth of 5% is not great, Pre-tax margin of 27% is great, ROE of 17% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 10% and 10% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 69 which is a FAIR score but needs to improve its earnings, a RS Rating of 82 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 30 indicates it belongs to a strong industry group of Medical-Ethical Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Alivus Life Sciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-01-22 Quarterly Results
2025-11-06 Quarterly Results
2025-08-01 Quarterly Results
2025-05-15 Audited Results & Final Dividend
2025-01-23 Quarterly Results
Date Purpose Remarks
2025-09-01 FINAL Rs.5.00 per share(250%)Final Dividend
2023-10-17 INTERIM Rs.22.50 per share(1125%)Interim Dividend
2023-03-24 INTERIM Rs.21.00 per share(1050%)Interim Dividend
2021-11-23 INTERIM Rs.10.50 per share(525%)Interim Dividend
View Alivus Life Sciences Dividend History Arrow

Alivus Life Sciences F&O

Alivus Life Sciences Shareholding Pattern

74.91%
5.44%
0.27%
5.08%
0%
10.21%
4.09%

Alivus Life Sciences FAQs

Alivus Life Sciences share price is ₹1,046 As on 13 April, 2026 | 07:27

The Market Cap of Alivus Life Sciences is ₹12841.3 Cr As on 13 April, 2026 | 07:27

The P/E ratio of Alivus Life Sciences is 23.6 As on 13 April, 2026 | 07:27

The PB ratio of Alivus Life Sciences is 4.1 As on 13 April, 2026 | 07:27

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23